Intranasal esketamine: real-world clinical practice in treatment-resistant depression and factors associated with treatment response.
BMC Psychiatry March 17, 2026 Bernhard T Baune, Kevin Rosemann, Dimitri Hefter et al. 2 citations
BACKGROUND: Intranasal esketamine has recently emerged as an innovative treatment option for treatment-resistant depression (TRD). This retrospective, uncontrolled study aimed to evaluate the real-world effectiveness of esketamine in an naturalistic inpatient setting and explore demographic and clinical factors associated with treatment response. METHODS: We conducted a chart review of 101...
DOI: 10.1186/s12888-026-07980-8 (opens in new tab)
Full text (opens in new tab)
Mdd
Humans
Antidepressive agents
Treatment outcome
+10